NCT01986933

A Phase 2 Study of CIM331 for Atopic Dermatitis Patients

A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF CIM331 IN ATOPIC DERMATITIS PATIENTS WHO ARE INADEQUATELY CONTROLLED BY OR INTOLERANT TO TOPICAL THERAPY

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 264 (actual)
• Sponsor: Chugai Pharmaceutical · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

To assess the safety, tolerability and efficacy of CIM331, compared to placebo, in atopic dermatitis patients who are inadequately controlled by or intolerant to topical therapy

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	nemolizumab (CIM331)
OTHER	Placebo

Timeline

• Start date: 2013-11-01
• Primary completion: 2015-04-01
• Completion: 2016-06-01
• First posted: 2013-11-19
• Last updated: 2022-01-25
• Results posted: 2021-11-22

Locations

18 sites across 1 country: United States